Tango Therapeutics Inc TNGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNGX is a good fit for your portfolio.
News
-
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
-
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
-
Tango Therapeutics Announces Discontinuation of TNG348 Program
-
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
-
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
Trading Information
- Previous Close Price
- $7.16
- Day Range
- $6.83–7.12
- 52-Week Range
- $2.88–13.03
- Bid/Ask
- $6.15 / $6.92
- Market Cap
- $739.38 Mil
- Volume/Avg
- 336,546 / 631,401
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 140
- Website
- https://www.tangotx.com
Comparables
Valuation
|
Metric
|
TNGX
|
VOR
|
CTIC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.78 | 0.68 | — |
Price/Sales | 18.45 | — | 14.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TNGX
|
VOR
|
CTIC
|
|---|---|---|---|
Quick Ratio | 7.33 | 8.13 | 1.20 |
Current Ratio | 7.54 | 8.46 | 1.27 |
Interest Coverage | — | — | −3.20 |
Quick Ratio
TNGX
VOR
CTIC
Profitability
|
Metric
|
TNGX
|
VOR
|
CTIC
|
|---|---|---|---|
Return on Assets (Normalized) | −23.42% | −48.29% | −46.52% |
Return on Equity (Normalized) | −38.32% | −61.06% | — |
Return on Invested Capital (Normalized) | −35.16% | −54.20% | −143.40% |
Return on Assets
TNGX
VOR
CTIC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Kgdxmrtbw | Bgrjmph | $124.7 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hlxhtdhj | Dhpqrp | $110.4 Bil | |||
| Moderna Inc
MRNA
| Jtkmqcss | Wjkk | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Xwyhjdfd | Mvnzv | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Jkrfdmp | Bcpk | $22.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fbdtmmlgk | Gmjtmk | $19.4 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Txkghfgrd | Qbbbsb | $15.3 Bil | |||
| Incyte Corp
INCY
| Cwxsgzvc | Ylyyfnn | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Zwkwvsspv | Nftbjgf | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Csqtcncbv | Lnf | $12.2 Bil |